右雷佐生(Dexrazoxane Hydrochloride) - 药物靶点：Top II_在研适应症：转移性乳腺癌，诊断和治疗物质外渗，细胞保护佐剂_专利_临床

概要

基本信息

药物类型

小分子化药

别名

dexrazoxane、Topotect、Totect

+ [13]

靶点

Top II

作用方式

抑制剂

作用机制

Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病其他疾病

在研适应症

转移性乳腺癌诊断和治疗物质外渗细胞保护佐剂

非在研适应症

支气管炎心肌疾病出血

原研机构

Clinigen Ltd.

在研机构

CNX Therapeutics Ltd.

Kissei Pharmaceutical Co., Ltd.

Reach Pharmaceuticals Pty Ltd.

+ [1]

非在研机构

Valerio Therapeutics SA

Clinigen Ltd.

Pfizer Inc.

权益机构

CNX Therapeutics Ltd.

Clinigen Ltd.

Er-Kim Ilaç Sanayi ve Ticaret AS

最高研发阶段批准上市

首次获批日期

美国 (1995-05-26),

心肌疾病转移性乳腺癌

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C11H17ClN4O4

InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N

CAS号149003-01-0

关联

54

项与右雷佐生相关的临床试验

NCT06647953

/ Recruiting临床3期IIT

Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB.
Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor.
The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. Topotecan is in a class of medications called topoisomerase I inhibitors. It works by interfering with tumor cell DNA which kills them. Giving topotecan in addition to standard IVADo and IVA chemotherapy regimens may shrink the cancer as well as or better than the standard therapy or could decrease the chance the tumor spreads while causing fewer side effects.

开始日期2025-03-21

申办/合作机构

The Children's Oncology Group Foundation, Inc.

NCT06220032

/ Recruiting临床3期IIT

ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial

Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corresponds to a cumulative incidence of 5-10% within 5-years after receiving R-CHOP. In the elderly, an incidence of 26% has been reported after 8-years of follow-up. Among patients who die in complete remission, heart failure has been described to be one of the most important causes of death. ANTICIPATE aims to evaluate if dexrazoxane can prevent AICD in DLBCL patients and identify those at highest risk of AICD. Of all patients treated with anthracyclines in a first-line setting, DLBCL patients were chosen for this trial for two primary reasons. Firstly, these patients have a favourable oncological prognosis with a 5-year relative survival in the Netherlands of 64-78% in those aged 18-74 years increasing the importance of preventing long-term toxicity. Secondly, the cumulative anthracycline dose used for the treatment of DLBCL is higher than the dose used in breast cancer. The cumulative anthracycline dose is the most important risk factor for AICD known.

开始日期2024-08-15

申办/合作机构

Hemato-Oncologie voor Volwassenen Nederland

NCT06262438

/ Recruiting临床2期IIT

A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity. The linked Quizartinib trial (CHIP-AML22/Quizartinib) is a phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric AML patients with a FLT3-ITD mutation and NPM1 wild-type.

开始日期2024-02-06

申办/合作机构

Princess Maxima Centre For Pediatric Oncology

[+1]

100 项与右雷佐生相关的临床结果

登录后查看更多信息

100 项与右雷佐生相关的转化医学

登录后查看更多信息

100 项与右雷佐生相关的专利（医药）

登录后查看更多信息

1,044

项与右雷佐生相关的文献（医药）

2025-12-01·Natural Products and Bioprospecting

Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agents

Article

作者: Liu, Yu-Ming ; Wang, Li-Ning ; Gou, Xiang-Bo ; Yang, Shu-Han ; Hua, Xin-Hao ; Wang, Fa-Qi ; Xu, Yun-Sheng ; Liu, Yuan ; Shao, Chen-Yue

Abstract:

Natural products are the important sources in cardiovascular drug development. In this study, twenty-nine buthutin derivatives were designed, synthesized, and evaluated for their NHE-1 inhibition and protective effects on cardiomyocyte injury. The structure of the newly synthesized compounds had been confirmed by 1H-NMR, 13C-NMR, and HR-ESI-MS spectra. Among all target compounds at 1 μM, compounds 9d, 9f, 9k, 9m, and 9n, with a protection ratio exceeding 30%, exerted stronger protective effects on H9c2 cardiomyocyte than positive control dexrazoxane and buthutin A. Meanwhile, compounds 9k, 9m, and 9o showed the significant NHE-1 inhibitory activities on H9c2 cardiomyocyte, all with a dpHi/min value less than 0.23. What is more, compounds 9k, 9m, 9o and buthutin A all exhibited the specificity on NHE-1 inhibition. Molecular modelling studies suggested the ability of compounds 9m and 9o to establish interactions with three hydrogen bonds to Asp267 and Glu346 of NHE-1, but also the ability with much lower CDOCKER energies than positive control cariporide and buthutin A. The structure–activity relationship (SAR) studies suggested that the presences of amide group, four-carbon linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two pharmacological actions. This research would open new avenues for developing amide-guanidine-based cardioprotective agents.Graphical Abstract

2025-11-01·BREAST CANCER RESEARCH AND TREATMENT

Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Miller, Kyle J ; Rahman, Muhammad Aziz ; Grace, Fergal ; Vacharanukrauh, Pinyadapat ; Alif, Sheikh M

Abstract:

Purpose:

This study aimed to systematically assess the efficacy of cardioprotective agents in preventing anthracycline-induced cardiotoxicity in patients with breast cancer using a comprehensive network meta-analysis (NMA).

Methods:

This study included patients with breast cancer undergoing anthracycline-based chemotherapy. Randomized controlled trials (RCTs) published before March 2020 were identified through systematic searches in MEDLINE, Cochrane CENTRAL, Web of Science, and CINAHL. The primary outcome was left ventricular ejection fraction (LVEF), assessed using cardiac magnetic resonance imaging, multigated radionuclide angiography, or echocardiography. The NMA integrated direct and indirect comparisons to estimate the relative effectiveness of pharmacological interventions.

Results:

The systematic review included 31 RCTs with 3,228 participants, whereas the NMA synthesized 25 effect sizes from 15 RCTs. Mineralocorticoid receptor antagonists (MRAs) [standardized mean difference (SMD): −1.78, 95% confidence interval (CI): −2.81 to −0.75] and trimetazidine (SMD: −1.12, 95%CI: −2.32 to −0.09) exhibited the most substantial cardioprotective effects. Dexrazoxane (SMD: −0.53, 95%CI: −1.90 to −0.02) and β-blockers (SMD: −0.34, 95%CI: −0.70 to 0.02) showed potential benefits, albeit with greater uncertainty. Direct comparisons showed that dexrazoxane was more effective than β-blockers (SMD: −1.25, 95%CI: −2.22 to −0.48), with mineralocorticoid receptor antagonists (MRAs) outperforming both. Despite heterogeneity and potential publication bias, mineralocorticoid receptor antagonists (MRAs) and trimetazidine consistently ranked as the most effective interventions. LVEF findings confirmed the cardioprotective benefits of β-blockers, ARBs, ACE inhibitors, and dexrazoxane.

Conclusions:

RCT evidence suggested that cardioprotective drugs effectively mitigate anthracycline-induced LVEF decline. However, the lack of direct head-to-head trials limits definitive conclusions on comparative efficacy, warranting trials in patients with lower baseline LVEF to optimize cardioprotective strategies.

2025-09-01·British Journal of Pharmacology

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

Article

作者: van der Kraak, Petra ; Lapré, Thirza A. ; van der Harst, Pim ; Sluijter, Joost P. G. ; Mokhles, M. Mostafa ; Kelters, Ilse R. ; van Laake, Linda W. ; de Boer, Teun P. ; van Ham, Willem B. ; Benavente, Ernest Diez ; Teske, Arco J. ; Sampaio‐Pinto, Vasco ; Arends, Bauke ; van der Geest, Jort S. A. ; Dendorfer, Andreas ; Doevendans, Pieter A.

Abstract:

Background and Purpose:

The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection.

Experimental Approach:

Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure hearts, then exposed to doxorubicin (Dox) to investigate cardiotoxic effects and to dexrazoxane (Dex) to explore cardioprotection. We assessed contractile function and glucose consumption, followed by evaluation of calcium transients, structural integrity and transcriptomic changes. Additionally, electrocardiogram (ECG) alterations were analysed in patients treated with anthracyclines to corroborate the cardiotoxicity findings from LMS.

Key Results:

We observed distinct functional responses to Dox, with LMS derived from some patients exhibiting high susceptibility to Dox‐induced cardiotoxicity. LMS from susceptible patients displayed reduced contractile function and excitability, myofibre dyssynchrony, structural damage and decreased metabolic activity. Dex pretreatment partially mitigated these effects, preserving contractile function and preventing structural damage. Consistent with ex vivo findings, patients treated with anthracyclines exhibited acute and chronic alterations in T‐, P‐ and R‐wave morphology of the ECG, confirming variable susceptibility at the clinical level.

Conclusions and Implications:

We highlight the value of human LMS in studying Dox‐induced cardiotoxicity and the cardioprotective potential of Dex, even when sourced from end‐stage heart failure patients. Susceptible patients harboured cardiomyopathy‐associated genetic mutations, suggesting that genetic screening including cardiomyopathy‐associated genes, prior to anthracycline treatment, could enable improved patient risk stratification. We demonstrate the potential utility of ECG changes for early detection of subclinical cardiotoxicity.

54

项与右雷佐生相关的新闻（医药）

2025-08-27

·药筛

医院没报量，还有机会吗？

这次11批国采医院报量，太难了！昨晚直播间里，有朋友说，广东报量非常难，不少医院都按通用名报量，不按厂牌，即使是对医院在销的厂牌产品，也是按通用名报量，而且数量上，尽量少报，不会超量。如果不在医院销售的产品，想要报量，难度就更大了。越是大医院，要求越严格。如果企业没有拿到医院报量，集采中选后，还有机会吗？答案是，看品种，不同产品机会不一样！第一类，原研主导型品种，机会最大最典型品种如罗沙司他胶囊，总计20个过评企业，2024年医院市场总计销售约4500万粒，100%来自原研珐博进。医院报量时，如果都按厂牌报量，数量最多的，当然是原研，其他光脚企业报量可忽略。如果集采时，原研不中选，其他中选企业，在主供区就可以分走部分报量。而有些光脚企业，之前能让医院按厂牌报量，产品中选后，还能保住非主供区的一些量，这就是额外赚到的。其他类似品种还有，奥拉帕利、阿伐曲泊帕、艾曲泊帕、达格列净等。第二类品种是，现有市场销售主要厂家，未过评，没资格参加国采，最典型品种如倍他米松注射剂。粉针剂和小水针年销额总计4亿元，大约2000万支。几乎全部来自粉针剂，和未过评的小水针1ml：5.26mg。医院现在报量，只能按通用名报量，这部分量，最后都会分给中选企业。另外，如果这些品种厂家较多，每个企业都不确定能否中选，即使中选，价格也比较低。因此，企业也不会花多少精力让医院按厂牌报量。这类品种企业中选后，在主供区域，就可以拿走报量。类似品种还有法莫替丁注射剂、奥司他韦颗粒剂、洛索洛芬凝胶贴膏、甲氧氯普胺注射剂、二羟丙茶碱注射剂、碳酸氢钠注射剂、腺苷钴胺等。第三类品种，是国产一家独大，光脚企业可能有捡漏机会。最典型品种如二甲双胍恩格列净片(I)。现有市场销售几乎全部来自华东医药，如果华东医药不中选，其他中选企业就可以分走报量。但是，按当前规则，华东医药有复活机会，企业如果选择最低价复活，其他企业的分量就很少，只能做增量。类似品种还有美索巴莫注射剂、地氯雷他定口服液体剂、右雷佐生注射剂、阿戈美拉汀等。第四类品种，现有市场份额分散，多个国产企业分市场，最痛苦。最典型品种如头孢唑肟注射剂。现有市场，西南药业、海口制药厂、福安、致君等，多家企业分市场。前期医院报量时，这些企业多少都能按厂牌报量。后期中选时，这些主导企业，不可能都不中选。因此，其他光脚企业捡漏的机会就很少。而且对于成熟品种，也很难有增量。这类品种的光脚企业最困难。其他类似品种还苯唑西林注射剂、尼可地尔、溴己新等。

带量采购生物类似药

2025-08-26

·GlobeNewswire-Health Care

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Partnership will broaden portfolio distribution of oncology products to cancer patients in the specified regionsWARSAW, Poland and LONDON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement with CNX Therapeutics to supply selected oncology products across Central & Eastern Europe (CEE) and Türkiye. The agreement creates an exclusive partnership for a portfolio of oncology-related medications – including CNX Therapeutics’ Cardioxane® (dexrazoxane) and Savene® (dexrazoxane) – that are part of CNX’s established oncology portfolio. Through this partnership, treatments will now be distributed across all CEE markets. “A trusted partner and dedicated provider of oncology treatments in the region, Er-Kim has been bringing innovative oncology-related medications to emerging EMEA for 40 plus years, and we are always looking for strategic collaborations that enhance our dedication to these markets,” said Mert Zorlular, President & CFO of Er-Kim. “We are excited about our partnership with CNX Therapeutics to support the expansion of its strong portfolio of pharmaceutical options for people with cancer as we strive to improve their well-being and quality of life.” Pete Butterfield, Chief Operating Officer at CNX Therapeutics, said, “This partnership represents a significant step forward in expanding our commercial reach. Er-Kim's extensive regional network across Central and Eastern Europe will enable us to access new markets through their established distribution infrastructure. This is just the beginning of what we expect to be a highly successful partnership." About Er-KimEstablished in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, setting new commercialization and patient access standards. Through strategic partnerships with over 40 global leaders, Er-Kim distributes more than 68 products to 50+ countries, revolutionizing patient care in international markets by solving complex distribution challenges. Er-Kim has a dedicated team of over 300 professionals worldwide and revenues exceeding EUR 305M. For more information, please visit https://www.er-kim.com/. About CNX TherapeuticsCNX Therapeutics is a specialty pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 60 markets worldwide, both directly and through strategic partnerships, and is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and Critical Care products, which is committed to the highest standards of ethics and sustainability. For more information, visit: www.cnx-therapeutics.com. Media contacts: Rosalia ScampoliMarketcom PRTel: (914) 815-1465rscampoli@marketcompr.com Mehdi JumaCNX Communications Managermehdi.juma@cnx-therapeutics.com

引进/卖出

2025-07-30

·医药代表

即将截止！第十一批国采工作提示

继续分享第十一批国采最新进展，信息填报工作将要到截止日期了。7 月 28 日，国家联采办发布《工作提示》，向各药品相关企业进行提醒，根据本月 15 日发布的《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，本阶段信息填报系统将于明日（7 月 31 日）16:00 停止填报，截至 7 月 31 日 17:00 审核通过的各厂牌药品信息将作为本次医疗机构填报需求量的选择范围；未在规定时间内填报信息并提交的药品，将不纳入医疗机构填报需求量的选择范围。《工作提示》要求，请已填报信息的相关企业关注系统内审核状态，还未填报信息的企业请按时间要求尽快开展填报工作。今日，业界也在讨论第十一批国采主要规则，主要规则《征求意见稿》在行业协会及医药人中流传，随着明日信息填报的结束，距离《采购文件》的发布应该是越来越近了。不知道进入本批国采范围的小伙伴们准备好了吗？▌ 55 个药品拟纳入第十一批国采7 月 15 日，国家联采办发布了《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》。《通知》显示，按照第十一批国家组织药品集中采购进度安排，国家组织药品联合采购办公室启动第十一批国家组织药品集中采购相关药品信息填报工作，共有 55 个药品拟纳入第十一批国采，名单如下：#品种名称1倍他米松注射剂2地氯雷他定口服液体剂3卢帕他定口服常释剂型4阿瑞匹坦口服常释剂型5福沙匹坦双葡甲胺注射剂6奥拉帕利口服常释剂型7右丙亚胺（右雷佐生）注射剂8达格列净口服常释剂型9二甲双胍恩格列净片(I)10普伐他汀口服常释剂型11硫酸镁钠钾口服用浓溶液12法莫替丁注射剂13瑞巴派特口服常释剂型14腺苷蛋氨酸注射剂15尼可地尔口服常释剂型16贝尼地平口服常释剂型17贝前列素口服常释剂型18西洛他唑口服常释剂型19阿伐曲泊帕口服常释剂型20艾曲泊帕乙醇胺口服常释剂型21腺苷钴胺口服常释剂型22罗沙司他口服常释剂型23地诺孕素口服常释剂型24钆布醇注射剂25美索巴莫注射剂26阿仑膦酸口服常释剂型27洛索洛芬贴剂/洛索洛芬贴膏剂28甲氧氯普胺注射剂29氯诺昔康注射剂30二羟丙茶碱注射剂31沙丁胺醇注射剂32丙卡特罗吸入剂33溴己新注射剂34福莫特罗吸入剂35异烟肼注射剂36奥司他韦颗粒剂37阿莫西林克拉维酸口服液体剂38头孢丙烯口服液体剂39头孢唑肟注射剂40苯唑西林注射剂41去氧肾上腺素注射剂42肾上腺素注射剂43碳酸氢钠注射剂44复方醋酸钠林格注射液/钠钾镁钙葡萄糖注射液45复方电解质注射剂46复方电解质注射剂（Ⅱ）47维库溴铵注射剂48布比卡因注射剂49阿戈美拉汀口服常释剂型50氟伏沙明口服常释剂型51尼麦角林口服常释剂型52奥卡西平口服常释剂型53多巴丝肼口服常释剂型54吡拉西坦（乙酰胺吡咯烷酮）口服常释剂型55尼达尼布口服常释剂型据环球网报道，国家医保局相关司负责人介绍，第十一批国采经过三阶段筛选，将此 55 个品种纳入第十一批集采报量范围，采购规则总体将坚持“稳临床、保质量、防围标、反内卷”的原则。除此之外，随《通知》还发布了《评数量达到条件未纳入第十一批集采的药品》，以及具体原因。你的品种被纳入第 11 批国采报量名单了吗？欢迎留言分享~相关阅读：四十年，一家跨国药企的中国故事医药人变身公益侠，全球公益接力正式版来了！2025国谈时间确定2024年全球药品销售20强百万人从社会“消失”，药企VR破局官宣了，国药股份董事长确定康方生物代表被查，官方结果公布一药企总裁被罚1500万，10年禁入美威胁200%医药关税，引多国警惕第十一批国采报量启动，55个品种阿斯利康开线下年会了，近4000人上市药企90后少帅，突然辞去所有职务三度亮相链博会，诺和诺德以“链”会友家族药企，创始人辞职，管理层更换9900万元创新药“破题”基金！申报开启骨科主任受贿两百万，分给他人一半多22年老将即将谢幕，诺华CFO完成交棒罗氏、默克人事变动，中国医药总经理辞职药企财务造假！多位高管将被重罚最新10个重点监控药品公布17家药企上榜25年《财富》中国500强百年跨国药企诚聘英才！BI招聘专场国家市监总局公告，一药企被罚近四千万第三家药企罚单落地，副总经理闪电辞职肺癌新突破！复宏汉霖WCLC“秀肌肉”中央巡视组进驻！李健被查又一跨国医药巨头CFO退休百济神州寻找发光的你（附全国职位）AZ前高管加盟，百时美施贵宝迎来新任CMO一医学专家被查，曾任三甲医院院长阿斯利康中国，架构调整拜耳新一轮招聘启动，这次机会不要错过中央巡视组进驻，前省卫健委主任主动投案18家药企上榜2025年《财富》世界500强诺和诺德新任总裁兼首席执行官确定国家药监局原副局长陈时飞被开除党籍MRCLUB原创作者招募中数十万精准会员每日阅读，助您快速提升个人品牌，扩大在医药行业及社会化媒体的影响力！（详情请访问网站http://wemr.club）医药代表伴您成长！

带量采购CSCO会议

100 项与右雷佐生相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07807	右雷佐生	V03AF02	DB00380

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
诊断和治疗物质外渗	欧盟	CNX Therapeutics Ltd.	2006-07-27
诊断和治疗物质外渗	冰岛	CNX Therapeutics Ltd.	2006-07-27
诊断和治疗物质外渗	列支敦士登	CNX Therapeutics Ltd.	2006-07-27
诊断和治疗物质外渗	挪威	CNX Therapeutics Ltd.	2006-07-27
细胞保护佐剂	中国	南京海润医药有限公司	2006-05-29
心肌疾病	美国	Pfizer Inc.	1995-05-26
转移性乳腺癌	美国	Pfizer Inc.	1995-05-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
出血	临床3期	丹麦	Valerio Therapeutics SA	2002-04-01
出血	临床3期	德国	Valerio Therapeutics SA	2002-04-01
出血	临床3期	意大利	Valerio Therapeutics SA	2002-04-01
出血	临床3期	荷兰	Valerio Therapeutics SA	2002-04-01
出血	临床3期	波兰	Valerio Therapeutics SA	2002-04-01
支气管炎	临床3期	丹麦	Valerio Therapeutics SA	2001-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03930680 (PHOENIX1, CTgov)	临床1期	心脏衰竭 \| 乳腺癌	25	Dexrazoxane (Dexrazoxane 100mg/m2)	齋鹹鬱壓獵願構衊廠鹹 = 膚襯鹽襯範憲齋鹽蓋齋繭夢窪餘鑰觸齋觸淵襯 (獵醖簾鹹衊繭選膚範壓, 襯憲餘憲顧齋簾積醖遞 ~ 蓋觸襯壓淵淵網範製衊) 更多	-	2025-06-12
				Dexrazoxane (Dexrazoxane 200mg/m2)	齋鹹鬱壓獵願構衊廠鹹 = 積衊鏇憲簾襯築網鏇構繭夢窪餘鑰觸齋觸淵襯 (獵醖簾鹹衊繭選膚範壓, 齋繭顧築糧廠網積觸鹹 ~ 構夢壓遞鏇構願艱鹽鹽) 更多
ESMO_ASIA2022	N/A	侵袭性非霍奇金淋巴瘤	263	PEG G-CSF	鹽遞衊衊憲鑰願鹹遞遞(襯製廠鏇願淵艱願窪糧) = 衊壓觸齋鏇膚簾襯廠簾膚鏇築顧鑰網簾鹹簾網 (膚獵積衊選範鏇鬱網淵 ) 更多	-	2022-12-03
				Non-PEG G-CSF	鹽遞衊衊憲鑰願鹹遞遞(襯製廠鏇願淵艱願窪糧) = 襯齋製憲觸網糧構鏇鏇膚鏇築顧鑰網簾鹹簾網 (膚獵積衊選範鏇鬱網淵 ) 更多
Pubmed \| Cancer	N/A	-	1,308	Doxorubicin with dexrazoxane	顧網醖構積築獵齋築衊(襯淵範餘鑰範艱衊壓簾): HR = 1.07 (95% CI, 0.78 ~ 1.47) 更多	-	2022-02-15
				Doxorubicin without dexrazoxane
NCT00038142 (CTgov)	临床2期	尤文肉瘤	46	Dexrazoxane+ImmTher+Cyclophosphamide+Doxorubicin+Vincristine (Arm A: VACdxr With ImmTher)	壓獵憲鑰積夢窪積憲積(鹹艱襯憲願範繭蓋襯糧) = 鏇獵築廠淵鹹糧衊餘獵齋鬱獵繭網範選糧構選 (獵憲鹹壓積齋繭廠壓齋, 壓鬱鬱膚憲窪選鑰襯觸 ~ 醖廠鬱蓋窪廠壓製鏇顧) 更多	-	2020-01-29
				Dexrazoxane+Cyclophosphamide+Doxorubicin+Vincristine (Arm B: VACdxr)	壓獵憲鑰積夢窪積憲積(鹹艱襯憲願範繭蓋襯糧) = 糧餘鹹蓋鏇淵製襯範襯齋鬱獵繭網範選糧構選 (獵憲鹹壓積齋繭廠壓齋, 鹹糧鏇鬱繭選願衊膚壓 ~ 艱顧憲蓋糧齋壓齋製鬱) 更多
NCT00928200 (CTgov)	临床1期	蛋类过敏 \| 复发性儿童急性淋巴细胞白血病	1	Dexrazoxane+Doxorubicin+Dexamethasone+Hydrocortisone+Erwinase+Methotrexate+Vincristine+Cytarabine	繭獵餘鑰鹹鹹鏇鑰鏇齋 = 鑰選夢構積鑰製遞淵淵鏇簾網艱襯遞齋醖獵壓 (遞窪膚鏇鹽襯鹹遞顧蓋, 壓憲範膚範襯遞醖夢簾 ~ 鹹夢廠艱醖積願鹹遞憲) 更多	-	2019-02-19
AAML1031 (ASCO2018)	N/A	急性髓性白血病	1,014	Dexrazoxane	網淵簾膚觸鑰憲繭齋夢(夢壓願淵廠餘積顧夢顧) = 積淵衊積繭構齋簾餘鑰鏇範糧窪範製觸窪簾艱 (願繭膚構淵構選網艱鬱 ) 更多	积极	2018-06-01
				No Dexrazoxane	網淵簾膚觸鑰憲繭齋夢(夢壓願淵廠餘積顧夢顧) = 製淵遞壓壓範鏇觸鑰醖鏇範糧窪範製觸窪簾艱 (願繭膚構淵構選網艱鬱 ) 更多
NCT01596088 (CTgov)	临床1/2期	诊断和治疗物质外渗	2	Dexrazoxane	簾觸願艱憲製顧築夢繭 = 憲壓獵窪顧餘築鬱顧築築築鏇築繭構襯膚襯築 (衊壓膚構膚鑰築築齋鏇, 鏇艱遞齋獵鬱蓋醖餘襯 ~ 積夢鹽繭鹽廠遞淵選獵) 更多	-	2015-03-13
NCT00673179 (CTgov)	N/A	骨肉瘤	7	Surgery+Leucovorin+Doxorubicin+Methotrexate+cisplatin (Outpatient Chemotherapy)	遞憲夢遞鹹糧艱蓋繭積(積鑰糧鬱餘築夢淵艱醖) = 醖簾壓製醖夢簾糧糧糧鑰艱鑰壓鹹醖鬱餘齋築 (鹹簾積齋淵襯遞壓鹹蓋, 鹹蓋壓鹹鏇餘襯鏇餘鬱 ~ 獵醖廠獵糧構願壓夢壓) 更多	-	2014-09-10
				Surgery+Dexrazoxane+Mesna+Leucovorin+Doxorubicin+ifosfamide+Gemcitabine+Sargramostim+Methotrexate+cisplatin (Additional Risk-Adapted Outpatient Chemotherapy)	遞憲夢遞鹹糧艱蓋繭積(積鑰糧鬱餘築夢淵艱醖) = 築糧積獵憲淵鬱鏇觸獵鑰艱鑰壓鹹醖鬱餘齋築 (鹹簾積齋淵襯遞壓鹹蓋, 選選鏇製蓋醖淵獵醖膚 ~ 觸鹹製顧願膚獵鹹選襯) 更多
NCT00544778 (CTgov)	临床2期	复发肉瘤	7	neoadjuvant therapy+dexrazoxane hydrochloride+filgrastim+doxorubicin hydrochloride+ifosfamide+irinotecan hydrochloride	壓廠遞醖築遞獵選艱艱 = 選簾積網觸鏇膚襯鏇顧艱積衊網選淵糧廠構窪 (獵顧鑰襯齋淵繭襯窪鬱, 鬱壓遞衊蓋艱憲膚製窪 ~ 範鬱觸夢簾願夢齋繭鑰) 更多	-	2014-08-28
NCT00742924 (CTgov)	临床1期	转移性骨肉瘤	24	therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid)	築遞襯廠淵艱糧窪糧積 = 鑰網憲糧鹽艱鏇鹽顧網鹽艱壓製壓鹽襯餘淵壓 (夢構範壓製範艱網憲壓, 壓醖鏇齋範顧鬱齋鑰鹽 ~ 壓願蓋齋築構窪窪餘糧) 更多	-	2014-07-04
				therapeutic conventional surgery+dexrazoxane hydrochloride+Mesna+etoposide+Leucovorin Calcium+zoledronic acid+filgrastim+doxorubicin hydrochloride+ifosfamide+Cisplatin+methotrexate (Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid)	築遞襯廠淵艱糧窪糧積 = 獵夢鑰遞窪鏇淵鑰襯鑰鹽艱壓製壓鹽襯餘淵壓 (夢構範壓製範艱網憲壓, 構繭醖觸壓範範醖鏇鏇 ~ 夢窪鑰餘淵壓衊鹹衊夢) 更多